{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-007561","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.192711+00:00","generated_at":"2026-06-28T13:15:50.282036+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q3 net loss $33.1M ($0.78 loss per share); clinical programs advance","bullets":["Net loss $33.1M, EPS $(0.78) vs net loss $33.3M, EPS $(11.00) in Q3 2020.","R&D expenses $28.1M (up from $17.3M) on continued development of three CHB candidates and NASH drug.","Cash, cash equivalents and investments $242.7M as of Sep 30, 2021, down slightly from $243.5M.","Dosing of ASO candidate ALG-020572 in healthy volunteers started; STOPS cohorts (120, 200 mg) fully enrolled.","CTA filed for NASH candidate ALG-055009 (THR-β agonist); dosing in healthy volunteers expected Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-007561","json":"https://secwatch.observer/filing/0001171843-21-007561.json","markdown":"https://secwatch.observer/filing/0001171843-21-007561.md","text":"https://secwatch.observer/filing/0001171843-21-007561.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184321007561/0001171843-21-007561-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184321007561/f8k_110421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:15:50.282036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}